Biocon Ltd.
BIOCON
374.2
0.00 (0.48%)The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.
Shareholding Pattern
| On | Ind. Pro. | Fore. Pro. | FII/FPI | Mutual Funds | Banks | Insurance | Others | Non/Institution |
|---|---|---|---|---|---|---|---|---|
| 2024-09 | 40.36 | 20.28 | 5.93 | 7.97 | 0.02 | 6.23 | 0.22 | 18.99 |
| 2024-06 | 40.36 | 20.28 | 5.9 | 8.69 | 0.02 | 5.51 | 0.08 | 19.17 |
| 2024-03 | 40.36 | 20.28 | 5.63 | 8.57 | 0.01 | 5.01 | 0.09 | 20.05 |
| 2023-12 | 40.36 | 20.28 | 6.55 | 9.31 | 0 | 5.12 | 0.08 | 18.3 |
| 2023-09 | 40.36 | 20.28 | 7.97 | 8.26 | 0 | 5.76 | 0.06 | 17.32 |
| 2023-06 | 39.66 | 20.98 | 9.52 | 7.47 | 0 | 5.09 | 0.03 | 17.26 |
| 2023-03 | 39.66 | 20.98 | 10.2 | 7.19 | 0 | 4.68 | 0.03 | 17.27 |
| 2022-12 | 39.66 | 20.98 | 14.42 | 3.95 | 0 | 4.69 | -0.01 | 16.31 |
| 2022-09 | 39.66 | 20.98 | 15.79 | 3.21 | 0 | 4.55 | 0.00 | 15.81 |
Results
| On | Income from Inv. | Int. on Bank Bal. | Int. on Advances | Other Int. | Interest Earned | Interest Exp. | Net Interest Income | Expenditure | Operating Income | Other Income | Prov. & Contingencies | PBT | Tax | PAT | Net Profit | Consolidated Net Profit | Adjusted EPS(Rs.) | Gross NPA | Gross NPA(%) | Net NPA | Net NPA(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09 | 0 | 0 | 0 | 0 | 3590.4 | 225.6 | 3364.8 | 2905 | 717.9 | 32.5 | 0 | 98.4 | 71.3 | 27.1 | 27.1 | -16 | -0.13 | 0 | 0% | 0 | 0% |
| 2024-06 | 0 | 0 | 0 | 0 | 3432.9 | 236 | 3196.9 | 2812.5 | 1754.9 | 1134.5 | 0 | 1145.5 | 283.7 | 861.8 | 861.8 | 659.7 | 5.49 | 0 | 0% | 0 | 0% |
| 2024-03 | 0 | 0 | 0 | 0 | 3917.1 | 227 | 3690.1 | 3001.2 | 964.5 | 48.6 | 0 | 321.7 | 96.1 | 225.6 | 225.6 | 135.5 | 1.13 | 0 | 0% | 0 | 0% |
| 2023-12 | 0 | 0 | 0 | 0 | 3953.7 | 266.7 | 3687 | 3026.9 | 1492.3 | 565.5 | 0 | 832.3 | 54.9 | 777.4 | 777.4 | 660 | 5.50 | 0 | 0% | 0 | 0% |
| 2023-09 | 0 | 0 | 0 | 0 | 3462.3 | 247.7 | 3214.6 | 2720.7 | 899.5 | 157.9 | 0 | 238.5 | 41.6 | 196.9 | 196.9 | 125.6 | 1.05 | 0 | 0% | 0 | 0% |
| 2023-06 | 0 | 0 | 0 | 0 | 3422.6 | 233 | 3189.6 | 2708.2 | 807.9 | 93.5 | 0 | 216.9 | 34.8 | 182.1 | 182.1 | 101.4 | 0.84 | 0 | 0% | 0 | 0% |
| 2023-03 | 0 | 0 | 0 | 0 | 3773.9 | 248.8 | 3525.1 | 2776.6 | 1152.2 | 154.9 | 0 | 536.7 | 82.1 | 454.6 | 454.6 | 313.2 | 2.61 | 0 | 0% | 0 | 0% |
| 2022-12 | 0 | 0 | 0 | 0 | 2941.1 | 120.3 | 2820.8 | 2296.8 | 722.9 | 78.6 | 0 | 30.1 | -4.8 | 34.9 | 34.9 | -41.8 | -0.35 | 0 | 0% | 0 | 0% |
| 2022-09 | 0 | 0 | 0 | 0 | 2319.7 | 30 | 2289.7 | 1849 | 535.2 | 64.5 | 0 | 257.4 | 147.3 | 110.1 | 110.1 | 46.9 | 0.39 | 0 | 0% | 0 | 0% |
| 2022-06 | 0 | 0 | 0 | 0 | 2139.5 | 19.9 | 2119.6 | 1740.1 | 477.3 | 77.9 | 0 | 239.9 | 29.5 | 210.4 | 210.4 | 144.4 | 1.20 | 0 | 0% | 0 | 0% |